Literature DB >> 3402537

[125I]SCH 23982, a 'selective' D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexus.

D Hoyer1, A Karpf.   

Abstract

[125I]SCH 23982, a ligand reported to be very selective for dopamine D-1 receptors, binds with high affinity to membranes of pig choroid plexus (KD = 186 pM, Bmax = 142 fmol/mg protein). Saturation and competition experiments suggested that [125I]SCH 23982 labels a homogeneous population of sites. The rank order for affinity of agonists, 5-HT greater than or equal to DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) much greater than dopamine greater than fenoldopam, and antagonists, metergoline greater than mesulergine = mianserin greater than SCH 23390 greater than methiothepin greater than ketanserin greater than fluphenazine much greater than (-)-sulpiride greater than (+)-sulpiride, was compatible with labelling of 5-HT1C receptors by [125I]SCH 23982. It also correlates very significantly with [3H]mesulergine binding to pig choroid plexus membranes. The effects of SCH 23390 and its analogues should not be systematically attributed to an interaction with D-1 receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402537     DOI: 10.1016/0014-2999(88)90766-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

3.  Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393.

Authors:  C A Briggs; N J Pollock; D E Frail; C L Paxson; R F Rakowski; C H Kang; J W Kebabian
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Circadian rhythm in the responsiveness of central 5-HT2A receptor to DOI in rats.

Authors:  H Nagayama; J Q Lu
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.

Authors:  B Sadzot; J M Baraban; R A Glennon; R A Lyon; S Leonhardt; C R Jan; M Titeler
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization.

Authors:  D Hoyer; C Waeber; P Schoeffter; J M Palacios; A Dravid
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-03       Impact factor: 3.000

7.  Comparative biochemical pharmacology of central nervous system dopamine D1 and D2 receptors.

Authors:  T A Reader; E Molina-Holgado; K M Dewar
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

8.  Effects of sodium, lithium, and magnesium on in vitro binding of [3H]SCH23390 in rat neostriatum and cerebral cortex.

Authors:  E Gottberg; L Diop; B Montreuil; T A Reader
Journal:  Neurochem Res       Date:  1989-05       Impact factor: 3.996

9.  A dynamic role for dopamine receptors in the control of mammalian spinal networks.

Authors:  Simon A Sharples; Nicole E Burma; Joanna Borowska-Fielding; Charlie H T Kwok; Shane E A Eaton; Glen B Baker; Celine Jean-Xavier; Ying Zhang; Tuan Trang; Patrick J Whelan
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.